158 related articles for article (PubMed ID: 38150061)
61. The impact of changes in gadolinium-enhancement on disease progression in children with neurofibromatosis type 1-associated optic pathway glioma: a retrospective analysis.
Kotch C; Si SJ; Desai K; Caminada P; Lo Russo FM; Li Y; Liu GT; Avery RA; Fisher MJ
J Neurooncol; 2023 Sep; 164(3):741-747. PubMed ID: 37803102
[TBL] [Abstract][Full Text] [Related]
62. ADC Histogram Analysis of Pediatric Low-Grade Glioma Treated with Selumetinib: A Report from the Pediatric Brain Tumor Consortium.
Vajapeyam S; Brown D; Ziaei A; Wu S; Vezina G; Stern JS; Panigrahy A; Patay Z; Tamrazi B; Jones JY; Haque SS; Enterline DS; Cha S; Jones BV; Yeom KW; Onar-Thomas A; Dunkel IJ; Fouladi M; Fangusaro JR; Poussaint TY
AJNR Am J Neuroradiol; 2022 Mar; 43(3):455-461. PubMed ID: 35210278
[TBL] [Abstract][Full Text] [Related]
63. Improving outcomes for neurofibromatosis 1-associated brain tumors.
Brossier NM; Gutmann DH
Expert Rev Anticancer Ther; 2015 Apr; 15(4):415-23. PubMed ID: 25652347
[TBL] [Abstract][Full Text] [Related]
64. Correlation Between Ophthalmologic and Neuroradiologic Findings in Type 1 Neurofibromatosis.
Godinho G; Esteves-Leandro J; Alves G; Madeira C; Faria O; Brandão E; Magalhães A; Falcão-Reis F; Penas S
J Neuroophthalmol; 2022 Mar; 42(1):101-107. PubMed ID: 33770007
[TBL] [Abstract][Full Text] [Related]
65. Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision.
de Blank PMK; Fisher MJ; Liu GT; Gutmann DH; Listernick R; Ferner RE; Avery RA
J Neuroophthalmol; 2017 Sep; 37 Suppl 1(Suppl 1):S23-S32. PubMed ID: 28806346
[TBL] [Abstract][Full Text] [Related]
66. Comparison of multi-shot and single shot echo-planar diffusion tensor techniques for the optic pathway in patients with neurofibromatosis type 1.
Ho CY; Deardorff R; Kralik SF; West JD; Wu YC; Shih CS
Neuroradiology; 2019 Apr; 61(4):431-441. PubMed ID: 30684113
[TBL] [Abstract][Full Text] [Related]
67. Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1.
de Blank PM; Berman JI; Liu GT; Roberts TP; Fisher MJ
Neuro Oncol; 2013 Aug; 15(8):1088-95. PubMed ID: 23658320
[TBL] [Abstract][Full Text] [Related]
68. Clinical signs and genetic evaluation of patients with neurofibromatosis type 1 with and without optic pathway gliomas in a center in Turkey.
Sharafi P; Varan A; Ersoy-Evans S; Ayter S
Childs Nerv Syst; 2024 Feb; 40(2):511-515. PubMed ID: 37401974
[TBL] [Abstract][Full Text] [Related]
69. Neuroophthalmological management of optic pathway gliomas.
Lee AG
Neurosurg Focus; 2007; 23(5):E1. PubMed ID: 18004957
[TBL] [Abstract][Full Text] [Related]
70. Syndromic and sporadic pediatric optic pathway gliomas: review of clinical and histopathological differences and treatment implications.
Shamji MF; Benoit BG
Neurosurg Focus; 2007; 23(5):E3. PubMed ID: 18004965
[TBL] [Abstract][Full Text] [Related]
71. Vascular stenosis in a child with visual pathway glioma treated with bevacizumab: a case report and review of literature.
Pilotto C; Beshlawi I; Thomas A; Grundy RG
Childs Nerv Syst; 2018 Apr; 34(4):781-785. PubMed ID: 29249070
[TBL] [Abstract][Full Text] [Related]
72. Natural history of optic pathway gliomas in a cohort of unselected patients affected by Neurofibromatosis 1.
Trevisson E; Cassina M; Opocher E; Vicenzi V; Lucchetta M; Parrozzani R; Miglionico G; Mardari R; Viscardi E; Midena E; Clementi M
J Neurooncol; 2017 Sep; 134(2):279-287. PubMed ID: 28577031
[TBL] [Abstract][Full Text] [Related]
73. Rare case of optic pathway glioma with extensive intra-ocular involvement in a child with neurofibromatosis type 1.
Gupta V; Sabri K; Whelan KF; Viscardi V
Middle East Afr J Ophthalmol; 2015; 22(1):117-8. PubMed ID: 25624686
[TBL] [Abstract][Full Text] [Related]
74. Evaluation of optic nerve diameters in individuals with neurofibromatosis and comparison of normative values in different pediatric age groups.
Tosun M; Güngör M; Uslu H; Anık Y
Clin Imaging; 2022 May; 85():83-88. PubMed ID: 35259715
[TBL] [Abstract][Full Text] [Related]
75. Systematic MRI in NF1 children under six years of age for the diagnosis of optic pathway gliomas. Study and outcome of a French cohort.
Blanchard G; Lafforgue MP; Lion-François L; Kemlin I; Rodriguez D; Castelnau P; Carneiro M; Meyer P; Rivier F; Barbarot S; Chaix Y;
Eur J Paediatr Neurol; 2016 Mar; 20(2):275-281. PubMed ID: 26774135
[TBL] [Abstract][Full Text] [Related]
76. Parent-of-origin in individuals with familial neurofibromatosis type 1 and optic pathway gliomas.
Johnson KJ; Fisher MJ; Listernick RL; North KN; Schorry EK; Viskochil D; Weinstein M; Rubin JB; Gutmann DH
Fam Cancer; 2012 Dec; 11(4):653-6. PubMed ID: 22829012
[TBL] [Abstract][Full Text] [Related]
77. Automatic segmentation, internal classification, and follow-up of optic pathway gliomas in MRI.
Weizman L; Ben Sira L; Joskowicz L; Constantini S; Precel R; Shofty B; Ben Bashat D
Med Image Anal; 2012 Jan; 16(1):177-88. PubMed ID: 21852179
[TBL] [Abstract][Full Text] [Related]
78. Longitudinal measures of visual function, tumor volume, and prediction of visual outcomes after treatment of optic pathway gliomas.
Kelly JP; Leary S; Khanna P; Weiss AH
Ophthalmology; 2012 Jun; 119(6):1231-7. PubMed ID: 22364864
[TBL] [Abstract][Full Text] [Related]
79. A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations.
Sharif S; Upadhyaya M; Ferner R; Majounie E; Shenton A; Baser M; Thakker N; Evans DG
J Med Genet; 2011 Apr; 48(4):256-60. PubMed ID: 21278392
[TBL] [Abstract][Full Text] [Related]
80. Pediatric Optic Pathway Gliomas Resource Utilization and Prevalence in the OptumLabs Data Warehouse.
Stoddard-Bennett TN; Yu F; Spiegel SJ; Perez CF; Coleman AL; Repka MX; Pineles SL
J Neuroophthalmol; 2024 Mar; 44(1):10-15. PubMed ID: 37505911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
